Who Supplies Vildagliptin to India from GERMANY

To import finished pharmaceutical formulations containing Vildagliptin into India, obtaining an import license from the Directorate General of Foreign Trade (DGFT) is mandatory. Additionally, the Central Drugs Standard Control Organization (CDSCO) requires registration of the product, which involves submitting Form CT-20/40/41, depending on the product type. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), stability data (preferably ICH Zone IV), and a No Objection Certificate (NOC) from the manufacturer. The timeline for import drug registration can vary but typically ranges from 6 to 12 months. For formulations under HS Code 30049099, compliance with the Drugs and Cosmetics Act and associated rules is essential.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, preferably in ICH Zone IV conditions, should be provided to demonstrate the product's shelf-life in India's climate. Port inspection by customs drug inspectors is conducted to ensure adherence to regulatory standards. If a batch fails quality testing, it may be rejected, leading to potential delays and additional costs.

In April 2025, the CDSCO mandated that all imported drugs, including finished pharmaceutical formulations, require import registration and a license as per the Drugs and Cosmetics Act and associated rules. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The Public Health Initiatives (PHI) scheme, introduced in 2024, offers incentives for domestic manufacturing of pharmaceutical products, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may influence import policies.

India imports finished Vildagliptin formulations primarily due to the demand for patented or branded products not manufactured domestically. Specific dosage forms, such as combination tablets, may not be produced locally, necessitating imports. While India has a significant domestic pharmaceutical industry, certain specialized formulations are imported to meet market needs. The market size for Vildagliptin formulations in India is substantial, with imports contributing to a portion of the total demand.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Education Cess of 2% and a Secondary Higher Education Cess of 1% are applicable, totaling 3%. A Countervailing Duty (CVD) of 6% is also imposed. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) rate varies based on the product classification. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) determines that imports are causing injury to domestic industries. Exemption notifications may reduce or eliminate certain duties under specific conditions. The total landed duty percentage varies depending on the product's classification and applicable exemptions.

India sources finished Vildagliptin formulations from Germany due to the availability of patented formulations and specialized dosage forms not produced domestically. Germany's pharmaceutical industry is known for high-quality standards and compliance with international regulations, providing a competitive advantage. Other suppliers, such as China and the United States, also export Vildagliptin formulations to India. Germany's share in the Indian market is significant, reflecting its strong position as a supplier.

India imports finished Vildagliptin formulations from Germany due to the availability of patented formulations and specialized dosage forms not produced domestically. Germany's pharmaceutical industry offers high-quality products that meet international standards, providing a competitive edge in the Indian market. Specific formulations, such as combination tablets, may not be manufactured in India, necessitating imports to meet patient needs.

Compared to other origins like China and the United States, Germany offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. German pharmaceutical products are known for their adherence to international standards, ensuring safety and efficacy. While other countries may offer lower prices, Germany's reputation for quality and compliance makes it a preferred source for specialized formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or regulatory delays. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks.

1. 1Engage in dual-sourcing strategies to reduce dependency on a single supplier.
2. 2Implement robust inventory planning to manage supply chain disruptions.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Establish minimum order quantities (MOQs) that align with market demand and storage capabilities.
5. 5Conduct thorough supplier qualification processes to ensure compliance with regulatory standards and quality expectations.

1. 1Obtain a valid Importer Exporter Code (IEC) from the DGFT.
2. 2Register the product with the CDSCO by submitting the appropriate form (CT-20/40/41).
3. 3Secure a Drug Import License from the CDSCO.
4. 4Obtain a No Objection Certificate (NOC) from the